| Combined effects of angiostatin and ionizing radiation in antitumour therapy HJ Mauceri, NN Hanna, MA Beckett, DH Gorski, MJ Staba, KA Stellato, ... Nature 394 (6690), 287-291, 1998 | 858 | 1998 |
| The contributions of cyclooxygenase-2 to tumor angiogenesis S Gately Cancer and metastasis reviews 19, 19-27, 2000 | 551 | 2000 |
| Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy S Gately, WW Li Seminars in Oncology 31, 2-11, 2004 | 505 | 2004 |
| The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin S Gately, P Twardowski, MS Stack, DL Cundiff, D Grella, FJ Castellino, ... Proceedings of the National Academy of Sciences 94 (20), 10868-10872, 1997 | 399 | 1997 |
| Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. SS Brem, D Zagzag, AM Tsanaclis, S Gately, MP Elkouby, SE Brien The American journal of pathology 137 (5), 1121, 1990 | 293 | 1990 |
| Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin S Gately, P Twardowski, MS Stack, M Patrick, L Boggio, DL Cundiff, ... Cancer Research 56 (21), 4887-4890, 1996 | 289 | 1996 |
| Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin DH Gorski, HJ Mauceri, RM Salloum, S Gately, S Hellman, MA Beckett, ... Cancer research 58 (24), 5686-5689, 1998 | 270 | 1998 |
| Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and … GA Soff, J Sanderowitz, S Gately, E Verrusio, I Weiss, S Brem, HC Kwaan The Journal of clinical investigation 96 (6), 2593-2600, 1995 | 213 | 1995 |
| β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites D Frost, B Meechoovet, T Wang, S Gately, M Giorgetti, I Shcherbakova, ... PloS one 6 (5), e19264, 2011 | 193 | 2011 |
| Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase … S Takano, S Gately, ME Neville, WF Herblin, JL Gross, H Engelhard, ... Cancer research 54 (10), 2654-2660, 1994 | 190 | 1994 |
| Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation MS Stack, S Gately, LM Bafetti, JJ Enghild, GA Soff Biochemical journal 340 (1), 77-84, 1999 | 182 | 1999 |
| Antiangiogenic scheduling of lower dose cancer chemotherapy. S Gately, R Kerbel Cancer journal (Sudbury, Mass.) 7 (5), 427-436, 2001 | 176 | 2001 |
| Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis S Gately, R Kerbel Progress in Experimental Tumor Research 37, 179-192, 2003 | 163 | 2003 |
| Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds S Gately, R West Drug Development Research 68 (4), 156-163, 2007 | 162 | 2007 |
| Human Angiostatin Inhibits Murine Hemangioendothelioma Tumor Growth in Vivo BJ Lannutti, ST Gately, ME Quevedo, GA Soff, AS Paller Cancer research 57 (23), 5277-5280, 1997 | 142 | 1997 |
| Diverse roles of macrophage matrix metalloproteinases in tissue destruction and tumor growth SD Shapiro Thrombosis and haemostasis 82 (08), 846-849, 1999 | 135 | 1999 |
| Immunolocalization of basic fibroblast growth factor to the micro vasculature of human brain tumors S Brem, AMC Tsanaclis, S Gately, JL Gross, WF Herblin Cancer 70 (11), 2673-2680, 1992 | 135 | 1992 |
| Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. GA Soff, TL Cornwell, DL Cundiff, S Gately, TM Lincoln The Journal of clinical investigation 100 (10), 2580-2587, 1997 | 125 | 1997 |
| Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib ML Goodall, T Wang, KR Martin, MG Kortus, AL Kauffman, JM Trent, ... Autophagy 10 (6), 1120-1136, 2014 | 116 | 2014 |
| Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia JP McKearn, G Gordon, JJ Cunningham, ST Gately, AT Koki, JL Masferrer US Patent 6,858,598, 2005 | 79 | 2005 |
